Dexcom's recall is not primarily a sensor-malfunction story. It is a theft story with two lot numbers.

FDA says Dexcom uncovered theft of scrapped G7 continuous glucose monitoring sensors and notified potentially affected users. The notice names lots 1725204004 and 1725069002. [1] FDA's current recall index places the Dexcom notice beside the broader safety-alert stream, where its unusual fact pattern can be flattened into another device item. [2]

The mechanics read like a supply-chain crime file. Scrapping sensors that fail quality standards is routine; the failures are sent to a third-party vendor for destruction and recycling. Dexcom says two lots meant for that destruction were instead stolen beforehand, sold into ordinary commerce, and — in the company's word — used by some customers. The two lots fail for different reasons: one contains sensors that were never properly sterilized and carry an increased risk of skin infection; the other comes from a batch with an elevated internal testing failure rate and an increased risk of returning no readings at all. Neither failure is subtle to the person wearing it, but neither announces itself as "stolen property" on the box. [1]

The paper's June 2 account of diabetes-device safety as lot checking fits this notice, but with a twist. Omnipod was about a correction in distributed medical technology. Dexcom is about scrapped product allegedly escaping the channel.

The escape route has a name. Dexcom traced sales of the stolen sensors to Pharmsource, LLC, which it says is not an authorized distributor but supplies some independent pharmacies and durable medical equipment distributors in the United States. Pharmacies that bought from Pharmsource are told to audit their inventory; pharmacies supplied through authorized distributors are not implicated, and neither are educational samples. [1] That division of blame is unusually precise for a recall notice, and useful: it tells independent pharmacists exactly which purchase orders to pull.

That changes the reader task. Users should not merely ask whether G7 sensors can fail. Any medical device can fail. The immediate question is whether a box came from an authorized channel and whether its lot number matches 1725204004 or 1725069002. [1] Users with affected sensors are told to stop using them and request replacements through Dexcom's support line, and the company has published a serial-number lookup for boxes whose outer lot code needs confirmation. No severe adverse events had been reported when the notice issued. [1]

This is also why distribution integrity belongs in health coverage. A continuous glucose monitor is intimate technology. It touches skin, directs attention, and influences insulin decisions. But it is also inventory. It moves through warehouses, distributors, pharmacies, samples, and secondary markets. When scrapped product appears outside the intended path, safety depends on paperwork as much as engineering.

The research stack found no verified X status post that cleanly carried the notice, so the article should not pretend a discourse consensus exists. The clean record is FDA's notice. The clean instruction is narrower: check the lot, confirm the channel, and follow Dexcom's replacement or notification path if affected.

For patients, that is a small act of bureaucracy in the middle of disease management. It is also the difference between a device story and a rumor.

-- NORA WHITFIELD, Chicago